ITRI vs ACLX

For growth investors, Itron, Inc.

(ITRI) is the stronger pick with -3. 0% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). Itron, Inc. (ITRI) offers the better valuation at 12. 7x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Itron, Inc. (ITRI) a "Hold" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -2. 0% for Itron, Inc. (ITRI). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus ITRI's +97. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus Itron, Inc. 's 1. 53β — meaning ITRI is approximately -551% more volatile than ACLX relative to the S&P 500. On balance sheet safety, Arcellx, Inc. (ACLX) carries a lower debt/equity ratio of 24% versus 74% for Itron, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Itron, Inc.

(ITRI) is pulling ahead at -3. 0% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: Itron, Inc. grew EPS 25. 7% year-over-year, compared to -103. 5% for Arcellx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Itron, Inc.

(ITRI) is the more profitable company, earning 12. 7% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 12. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITRI leads at 13. 5% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ITRI: 65.

1% to $137. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). Itron, Inc. (ITRI) carries a higher beta of 1. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, ITRI: +97. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ITRI (Technology) and ACLX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ITRI is a small-cap deep-value stock; ACLX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.